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he truly representative of freshly isolated lipoproteins. However, the 
stock titrz and the dialysis conditions were not, different among the 
groups. Recently. we reported ‘that vitamin E was also deficient in 
plasma from patients with variant angina (2). The vitamin E level was 
found to be significantly correlated between isolated LDL fraction that 
had been dialyzed and plasma (2). Fatty acid composition may also 
affect LDL oxidizability and remains to be determined. as suggested by 
Napoli. We agree that the propagation phase of lipid peroxidation is a 
more adequate estimation of LDL susceptibility to peroxidation. as 
suggested by Napoli, although the production of thiobarbituric acid- 
reactive substances after 24-h incubation with 0.5 pmohliter Cu” was 
used as a convenient index for the resistance or oxidizability in a 
previous study (3) and in the present study as well. 
Our study demonstrated an association between vitamin E defi- 
ciency and coronary spasm. However, the exact causal relation be- 
tween them is unkrown. The low levels of vitamin E may be the result 
of exhaustion of this antioxidant by increased lipid oxidatior stress, 
such as free radical production induced by frequently repeated alter- 
ation between severe transient regional myocardial &hernia and 
reperfusion. In contrast, it is also possible that the oxidiaability of LDL 
could be directly related to the pathogenesis of coronap. spasm. 
Oxygen-derived free radicals within the vasculature may initiate a 
vicious cycle by oxidizing LDL. which in turn may inhibit endnthelium- 
dependent vacrdilation and may also potenti:te agonist-induced vaso- 
constriction, leading to transient regional myocardial ischemia. Vita- 
min E deficiency may be involved in this vicious cyLle in the 
pathogenesis of coronary artery spasm. 
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Non-Q Wave Infarction After 
Thrombolytic Therapy 
1 am concerned by the potential for misinterpretation of data pre- 
sented by Langer et al. (1) with respect o non-Q wave infarction after 
thrombolytic therapy in the Late Assessment of Thrombolytic Eflicacy 
(LATE) study. They interpret their results to show that “patients with 
a non-Q wave infarction who have received thrombolytic therapy may 
have a better prognosis than those given placebo.” Although t!x &tdy 
is provocative in many .regar&. as presented it rakes substantial 
~concem for misin!erpretation and bias. 
Non-Q wave myocardial infarction was determined at hospital 
diiharge. Hence, it was not a baseline variable (present at the time of 
randomiaation), but rather an “outcome variable.” As such, it was 
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subject to bias, for example. a treatment effect that most likely led to 
noncomparable groups (i.e.. the comparability expected at randomiza- 
tion was lost). A greater percentage of patients with ST segment 
elevation myocardial infarction (MI) treated at baseline may have 
developed non-Q wave infarction, yielding an overaii group with a 
better prognosis. A second and somewhat related problem is defini- 
tional. On the presenting elt=ztrocardiogram, ST elevation versus 
non-ST elevation can be determined. but on!! at discharge can a clear 
interpretation of non-Q wave r’ersus Q wave Ml be made. The two 
contrasts are not equivalent. ST elevation MI may evolve to non-Q 
wave MI, and. less commonly, patients initially presenting without ST 
elevation may evolve through additional changes, resulting in Q wave 
MI. Finally. as the authors point out, their results arc post hoc 
analyses. They propose two new treatment-related hypotheses: First, 
patients with ST elevation presenting “late” benefit from thrombolytic 
therapy only if treated within 3 h of symptom onset, whereas those 
presenting late but treated late show an adverse trend. This hypothesis 
suggests that two fundamentally different groups of patients were 
recruited into rhe LATE study and that these two groups need to be 
better defined. One group of patients with prolonged pain (~6 h) and 
marked ST depression (>2 mm) may benefit from thrombolysis, 
although previous stutdics have shown that these patients, presenting 
early. will not benefit. In view of the much larger data base including 
studies showing an absence of benefit with ST depression using 
primary hypothesis testing (Thrzb~lysis iu Myocardial Lfarction- 
III), the contradictory findings of Langer et al. clearly will require 
prospective verification. 
Given the potential for bias and for confusion of these data and the 
unusual heterogeneity of patient groups recruited, a cautionary note 
should be raised. It certainly would be unwise to change our current 
thrombolytic therapy algorithm for acute MI on the basis of the results 
presented by Langcr et al. 
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We appreciate the opportunity to amplify further some issues arising 
from our recent report and raised by Anderson’s thoughtful letter. 
Rccause non-Q wave myocardial infarction is a diagnosis made 
retrospectively and not on hospital admission, Anderson raises con- 
cerns that it is subject to bias. Importantly. however. patients in the 
Late Assessment of Myocardial Efficacy (LATE) study (I) presenting 
with ST segment elevation developed non-Q wave myocardial infarc- 
tion with equal frequency in both tissue-type plasminogen- and 
placebo-treated groups, and the study remained randomized and 
placebo controlled. Hence, bias is unlikely. 
To be sure, there was heterogeny among patients enrolled in the 
LATE study, as hasbeen’the case with other large thrombolytie triak 
with a wide temporal window (International Study of Infarct Survival 
(ISIS] II). Patients in the LATE study with benefit from thrombolytie 
theram who had ST segment elevation were tkosc treated within 3 h of 
prcscntation to bospii not within 3 h ofsymptom onset; this point 
was identified as an important outcome variable in the initial IAfE 
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publication, The apparcutiy contradictory findings between our study 
and that of others are potentially rcconcdablc when one appreciates 
that patients with ST.segmcnt depression in the LATE study had at 
,least 2 mm-of ST depression. This group was not specifically addressed 
within the Thrombolysis in Myocardial Infarction 111 study (2) (tem- 
poral window U to IT h vs. 6 to 2J h in the LATE studv). Morcovcr, the 
natural history studies of Lee rt al. (3) have demonstrated that more 
prominent ST segment depression (i.c,.. 22 mm) is highly specific for 
the subsequent diagnosis of acute myocardial infarction and is also an 
indicator of increased risk. It is important to clarity that this group of 
patients did not have unusually prolonged pain but a prolonged time 
from the onset of pain to clinical presentation (i.e.. >6 h). 
We were careful to address obvious limitations of our study in the 
original manuscript and, in particular. did not advocate a change in the 
current thrombolytic therapy algorithm for acute myocardial infarc- 
tion. We remain convinced, however. that some patients with signifi- 
cant ST segment depression may benefit from thrombolytic therapy 
and are pleased that Anderson shares our interest in the need for 
prospective validation. 
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Basal Nitric Oxide Production by Diseased 
Coronary Arteries 
Egashira et al. (I) in their interesting study examined the effects of 
intracoronaty N”-monomethyl-L-arginine (LNMMA. ti inhibitor of 
nitric oxide synthesis) on basal coronary artery tone in Patients with 
variant angina and normal curonary arteries and in control subject 
They reported that tk comtrktor response to LNMMA was signiti- 
that 
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at the non$paslic sites. Their results indicate that the hasal rclrase of 
nitric oxidcis incrcascd rather than decreased at the spastic site in 
patients with variant angina. The authors did not examine the effect of 
atheroma on basal nitric oxide production. hut they acknowledge this 
limitation. This limitation is particularly relevant because many pa- 
tients with spasm have underlying atheroma. 
WC recently examined (2.3) the effects of an intracoronaty infusion 
of LNMMA in patients with chronic stable angina and coronary artcty 
discasc and in patienis with normal coronary arteriograms. The 
diameter of angiographically normal proximal and distal segments and 
coronary sttnoscs was measured by quantitative angiography. In 
response to an LNMMA infusion of 16 pmol’min for 4 min. there was 
a significant reduction (p < 0.01) in lumen diameter of the distal 
segments of diseased arteries and at the site of stenosis but no change 
(p = NS) in lumen diameter of the proximal segments (3). In patients 
with normal coronary artetiograms. there was a significant reduction 
(p < 0.01) in lumen diameter of both proximal and distal segments (2). 
These results indicate that basal nitric oxide production is pre- 
served at the site of stenotic atheromatous plaques. Because it appears 
to be absent in the proximal segments of diseased arteries in which the 
stenoses were mostly located, it is possible that regeneration of basal 
nitric oxide product& has occurred. There is some laboratory evi- 
dence ~osupport this hypothesis because the inducible isoform of nitric 
oxide synrhasc has been found in human atherosclerotic lesions ex 
\ ivo. where it is localized with macrophages. foam cells and vascular 
smooth muscle cells (4). Furthermore. the amount of nitric oxide 
synthase present is related to the severity of the lesion. WC therefore 
propose that atherosclerotic coronary arteries can regenerate basal 
uitric oxide production from an abnormal source. 
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